Published in Surgery Litigation and Law Weekly, July 4th, 2008
The '231 patent covers isolated adipose-derived stem cells and does not affect Cytori's commercialization of the Celution(R) System or the Company's product pipeline. However, Cytori believes that the court's decision is incorrect and that the University of California may elect to appeal the ruling.
Cytori was recently granted a foundational patent on its Celution(R) System device technology for processing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly